store at low temperature | store at -20°C
Rozanolixizumab(RYSTIGGO)是一种针对人类新生儿 Fc 受体(FcRn)的高亲和力人源化免疫球蛋白 G4 单克隆抗体,用于研究自身免疫和同种免疫疾病中致病性 IgG 。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,320 | 现货 | ||
5 mg | ¥ 5,970 | 现货 | ||
10 mg | ¥ 7,880 | 现货 | ||
25 mg | ¥ 11,900 | 现货 | ||
50 mg | ¥ 15,900 | 现货 |
产品描述 | Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases. |
靶点活性 | MDCK cells:0.98 nM, FcRn (human):23 pM(Kd), FcRn (monkey):25 pM(Kd) |
体外活性 | Demonstrating similar affinity at both pH 6.0 (Kd 23 pM and 25 pM for human and cynomolgus monkey, respectively) and pH 7.4 (34 pM and 53 pM for human and cynomolgus monkey, respectively), Rozanolixizumab binds to human FcRn and cynomolgus monkey FcRn[1].In a dose-dependent manner, Rozanolixizumab is observed to inhibit the recycling of human IgG by human FcRn-transfected MDCK cells, with an IC50 of 0.41 nM. The recycling of IgG is similarly inhibited in cynomolgus monkey FcRn-transfected MDCK cells (IC50 0.98 nM)[1].Additionally, Rozanolixizumab causes an increase in intracellular IgG AF647[1]. |
体内活性 | Demonstrating non-linear pharmacokinetics indicative of target-mediated drug disposition, intravenous (IV) dosing of rozanolixizumab in cynomolgus monkeys showed that single IV doses (30 mg/kg) reduced plasma IgG concentration by 69% by Day 7 post-administration. Throughout the treatment period of 42 days, daily IV administration of rozanolixizumab (initial 30 mg/kg loading dose; 5 mg/kg daily thereafter) consistently reduced plasma IgG concentrations in all cynomolgus monkeys, maintaining low concentrations[1]. |
别名 | UCB7665 |
分子量 | N/A |
CAS No. | 1584645-37-3 |
store at low temperature | store at -20°C
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Rozanolixizumab 1584645-37-3 Others UCB7665 UCB 7665 UCB-7665 Inhibitor inhibitor inhibit